Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Autism Spectrum Disorder Treatment Market

Autism Spectrum Disorder Treatment Market Share

Report ID: GMI11087
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Autism Spectrum Disorder Treatment Market Share

The market is marked by a highly competitive landscape, characterized by rapid innovation and technological progress. Prominent pharmaceutical companies hold a significant share of the market, driven by their extensive portfolios of advanced treatment options, including a variety of medications and emerging therapeutic modalities. Strategic initiatives, such as mergers, acquisitions, and collaborations, further strengthen the market position of key players, allowing them to expand their product offerings and access new markets.

Autism Spectrum Disorder Treatment Companies

The company profile section includes both companies that have commercial drugs available in the market as well as those that are onto clinical phase development. Prominent players operating in the autism spectrum disorder treatment industry include:

Service Providers
- Autism Research Institute
- Child Mind Institute, Inc.
- Cleveland Clinic
- Mayo Foundation for Medical Education and Research (MFMER)
- The General Hospital Corporation
Medication Manuafacturers
- Axial Therapeutics Inc.
- Bristol - Myers Squibb Company
- Curemark LLC
- Eli Lilly and Company
- F. Hoffmann - La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Novartis AG
- Otsuka Pharmaceutical Co., Ltd.
- PaxMedica
- Pfizer Inc

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The autism spectrum disorder treatment industry size was USD 34.1 billion in 2023 and is expected to grow at a 4.8% CAGR from 2024 to 2032 due to the rising prevalence of ASD, influenced by improved diagnostic criteria, heightened awareness, and genetic factors.

The children age group segment in the market recorded USD 25.3 billion in 2023 driven by increasing awareness, early diagnosis, and the rising prevalence of ASD among children.

The autism spectrum disorder treatment market from the hospitals end-use segment is expected to reach USD 20.1 billion by 2032 as they offer a multidisciplinary approach, integrating various medical, psychological, and therapeutic interventions

North America autism spectrum disorder treatment industry size is expected to grow at a 4.6% CAGR through 2032 led by the rising awareness and advancements in diagnostic methods